Current Position, Affiliation
- Professor, Department of Nephrology, Tohoku University School of Medicine, Japan
Education / Training
- 1997, M.D., University of Tokyo School of Medicine, Japan
- 2005, PhD., Division of Nephrology and Endocrinology, University of Tokyo Graduate School of Medicine, Japan
Professional and Research Experience
- 1999 - 2001, Resident, Kidney Center and Department of Internal Medicine, Mitsui Memorial Hospital, Japan
- 2006 - 2008, Visiting Scientist, Division of Nephrology and Hypertension, University of Erlangen-Nuremberg, Germany
- 2013 - 2019, Assistant Professor, Division of Nephrology and Endocrinology, University of Tokyo Graduate School of Medicine, Japan
- 2020 - 2022, Associate Professor, Division of Nephrology and Endocrinology, University of Tokyo Graduate School of Medicine, Japan
- 2022 - Present, Professor, Department of Nephrology, Tohoku University Graduate School of Medicine, Japan
Awards & Honors
- 2014, Young investigator's award of the Japanese Society of Nephrology
Selected Publications
- Novel anemia therapies in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Ku E, Del Vecchio L, Eckardt KU, Haase VH, Johansen KL, Nangaku M, Tangri N, Waikar SS, Więcek A, Cheung M, Jadoul M, Winkelmayer WC, Wheeler DC; for Conference Participants. Kidney Int. 2023 Oct;104(4):655-680.
- Controversies in optimal anemia management: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference. Babitt JL, Eisenga MF, Haase VH, Kshirsagar AV, Levin A, Locatelli F, Małyszko J, Swinkels DW, Tarng DC, Cheung M, Jadoul M, Winkelmayer WC, Drüeke TB; Conference Participants. Kidney Int. 2021 Jun;99(6):1280-1295.
- Update on diagnosis, pathophysiology, and management of diabetic kidney disease. Sugahara M, Pak WLW, Tanaka T, Tang SCW, Nangaku M. Nephrology (Carlton). 2021 Jun;26(6):491-500.
- Hypoxia-inducible factor activators: a novel class of oral drugs for the treatment of anemia of chronic kidney disease. Haase VH, Tanaka T, Koury MJ. Hematology Am Soc Hematol Educ Program. 2024 Dec 6;2024(1):409-418.
- Prolyl hydroxylase domain inhibitors as a novel therapeutic approach against anemia in chronic kidney disease. Sugahara M, Tanaka T, Nangaku M. Kidney Int. 2017 Aug;92(2):306-312.
Evolving Treatment Standards: Redefining Renal Anemia Care
Role
Speaker
Date & Time
12/05 16:40 - 16:55
Place
Room 3 ( 701C )
Lecture Title
The Role of Hypoxia-Inducible Factor Stabilizers in the Anemia Treatment Landscape